Global pharmaceutical company developing innovative medicines for diabetes, oncology, immunology, and neuroscience including breakthrough weight-loss drugs.
Profile & Fundamentals
Eli Lilly and: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Eli Lilly and Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company profile record
Eli Lilly and Company
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- Eli Lilly and Company
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇺🇸 United States
- Head office
- Lilly Corporate Center, Indianapolis, IN, United States, 46285
Leadership & scale
- Chief executive
- Mr. David A. Ricks
- CEO year born
- 1968
- Full-time employees
- 50K
- Fiscal year end
- December
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 1.03T
- P/E
- 38.7x
- Revenue (Q2 26)
- USD 23.0B
- Profit (Q2 26)
- USD 7.1B
- Dividend Yield
- 0.4%
- Revenue (FY 25)
- USD 65.2B
- Shares in public float
- 889M
- Insider ownership
- 0.16%
Reporting & identifiers
- Symbol
- LLY.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US5324571083
- Asset ID
- equity_61d2639f-a079-5015-93eb-1cbc9a373648
Ownership
Shares Outstanding
Latest: 893.7M | Max: 1.1B | Min: 893.7M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
99.47%
889.0M latest reported shares
Insider Ownership
0.16%
Latest reported insider stake
Short Float
0.01%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,052,023,000 |
| 2018-01-01 | 1,057,035,000 |
| 2019-01-01 | 957,526,000 |
| 2020-01-01 | 956,590,000 |
| 2021-01-01 | 953,653,000 |
| 2022-01-01 | 950,182,000 |
| 2023-01-01 | 903,980,000 |
| 2024-01-01 | 903,158,000 |
| 2025-01-01 | 898,002,000 |
| 2026-01-01 | 893,700,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| Lilly Endowment Inc | 90,376,978 | 10.14% | 2026-06-30 |
| BlackRock Inc | 66,380,842 | 7.45% | 2026-03-31 |
| Vanguard Capital Management, LLC | 53,361,774 | 5.99% | 2026-03-31 |
| PNC Financial Services Group Inc | 51,328,908 | 5.76% | 2026-03-31 |
| State Street Corp | 35,610,002 | 4% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 26,936,493 | 3.02% | 2026-08-31 |
| FMR Inc | 26,341,031 | 2.96% | 2026-03-31 |
| Vanguard 500 Index Investor | 21,016,458 | 2.36% | 2026-08-31 |
| Vanguard Portfolio Management, LLC | 20,977,027 | 2.35% | 2026-03-31 |
| Capital Research Global Investors | 20,873,140 | 2.34% | 2026-06-30 |
| Geode Capital Management, LLC | 20,191,864 | 2.27% | 2026-03-31 |
| Capital World Investors | 15,902,642 | 1.78% | 2026-06-30 |
| Morgan Stanley - Brokerage Accounts | 15,437,458 | 1.73% | 2026-03-31 |
| T. Rowe Price Associates, Inc. | 13,992,224 | 1.57% | 2026-03-31 |
| JPMorgan Chase & Co | 13,698,491 | 1.54% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The latest financial performance illustrates an extraordinary volume-driven expansion. Trailing twelve-month revenue surged to nearly eighty billion dollars, propelled by explosive prescription demand for diabetes and weight-loss blockbusters that overwhelmed single-digit price discounts. Net income expanded dramatically to over twenty-six billion dollars as fixed corporate overhead was spread across massive unit sales. However, headline accounting figures conceal important cash details. While trailing free cash flow reached a record twenty billion dollars, recurring multi-billion-dollar charges for acquired research partnerships continue to absorb cash. The underlying business is growing exceptionally fast, but investors must recognize that ongoing pipeline acquisitions remain an essential expense to maintain long-term leadership.
The latest financial performance illustrates an extraordinary volume-driven expansion. Trailing twelve-month revenue surged to nearly eighty billion dollars, propelled by explosive prescription demand for diabetes and weight-loss blockbusters that overwhelmed single-digit price discounts. Net income expanded dramatically to over twenty-six billion dollars as fixed corporate overhead was spread across massive unit sales. However, headline accounting figures conceal important cash details. While trailing free cash flow reached a record twenty billion dollars, recurring multi-billion-dollar charges for acquired research partnerships continue to absorb cash. The underlying business is growing exceptionally fast, but investors must recognize that ongoing pipeline acquisitions remain an essential expense to maintain long-term leadership.
Revenue, Net Income, and Free Cash Flow
Latest: USD 65.2B | Max: USD 65.2B | Min: USD -3.2B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 47x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability has expanded to historic highs, with gross profit margins reaching eighty-three percent and operating margins widening to nearly forty-six percent. This remarkable efficiency reflects immense manufacturing scale and a favorable shift toward high-margin metabolic treatments that cost relatively little to produce once factories are running. These elite margins face an inevitable tug-of-war. Growing government price caps and insurance rebates will push realized selling prices lower, but newly approved daily pills have much cheaper production and shipping costs than refrigerated injections. This structural cost advantage should keep long-term operating profit margins exceptionally strong near forty-four percent.
Profitability has expanded to historic highs, with gross profit margins reaching eighty-three percent and operating margins widening to nearly forty-six percent. This remarkable efficiency reflects immense manufacturing scale and a favorable shift toward high-margin metabolic treatments that cost relatively little to produce once factories are running. These elite margins face an inevitable tug-of-war. Growing government price caps and insurance rebates will push realized selling prices lower, but newly approved daily pills have much cheaper production and shipping costs than refrigerated injections. This structural cost advantage should keep long-term operating profit margins exceptionally strong near forty-four percent.
Profitability Margins
Latest: 83.0% | Max: 83.0% | Min: -1.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
83.0%
Gross profit / revenue
Operating Margin
45.6%
Operating income / revenue
Net Margin
31.7%
Net income / revenue
FCF Margin
13.8%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 21,222,100,000 | 2,737,600,000 | 3,759,000,000 |
| 2017-12-31 | 19,973,800,000 | -204,100,000 | 3,452,000,000 |
| 2018-12-31 | 21,493,300,000 | 3,232,000,000 | 2,506,300,000 |
| 2019-12-31 | 22,319,500,000 | 8,318,400,000 | 3,483,100,000 |
| 2020-12-31 | 24,539,800,000 | 6,193,700,000 | 4,470,500,000 |
| 2021-12-31 | 28,318,400,000 | 5,581,700,000 | 5,387,500,000 |
| 2022-12-31 | 28,541,400,000 | 6,244,800,000 | 4,600,400,000 |
| 2023-12-31 | 34,124,100,000 | 5,240,400,000 | -3,152,000,000 |
| 2024-12-31 | 45,043,000,000 | 10,590,000,000 | 414,300,000 |
| 2025-12-31 | 65,179,000,000 | 20,640,000,000 | 8,972,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 46.76 | Trailing four quarters |
| 2024-12-31 | 65.84 | Trailing four quarters |
| 2023-12-31 | 100.55 | Trailing four quarters |
| 2022-12-31 | 55.66 | Annual net income |
| 2021-12-31 | 47.19 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 73.09 | 18.24 | 12.9 | 17.71 |
| 2017-12-31 | 77.73 | 21.28 | -1.02 | 17.28 |
| 2018-12-31 | 78.22 | 28.04 | 15.04 | 11.66 |
| 2019-12-31 | 78.85 | 26.88 | 37.27 | 15.61 |
| 2020-12-31 | 77.66 | 29.38 | 25.24 | 18.22 |
| 2021-12-31 | 74.18 | 28.01 | 19.71 | 19.02 |
| 2022-12-31 | 76.77 | 30.32 | 21.88 | 16.12 |
| 2023-12-31 | 79.25 | 31.61 | 15.36 | -9.24 |
| 2024-12-31 | 81.31 | 37.83 | 23.51 | 0.92 |
| 2025-12-31 | 83.04 | 45.56 | 31.67 | 13.77 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.